Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

24 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-31

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational, case-control study evaluating the quantitative level of Septin9 in plasma pre- and post-colectomy in hereditary colorectal cancer (CRC) syndrome patients (Familial Adenomatous Polyposis (FAP), Lynch syndrome (also known as HNPCC), and Multiple Adenomatous Polyposis (MAP, also known as MYK/MYH) cases) and genetically related FAP-family members as controls and references.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay

NCT00696345

Colorectal Cancer

COMPLETED

PRESEPT Study: Evaluation of SEPT9 Biomarker Performance for Colorectal Cancer Screening

NCT00855348

Colorectal Cancer

COMPLETED

Hereditary Colorectal and Associated Tumor Registry Study

NCT00633607

Lynch Syndrome FAP Hereditary Diffuse Gastric Cancer +2 more

COMPLETED

Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes

NCT02371135

Lynch Syndrome Hereditary Colonic Polyposis Syndromes

ACTIVE_NOT_RECRUITING

CRC Screening Using mSEPT9 (Methylated Septin 9) in Chinese Population

NCT02540850

Colorectal Cancer Adenomatous Polyp of Colon Polyps +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Familial Adenomatous Polyposis Map Syndrome Lynch Syndrome Hnpcc Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient Group FAP

Clinical diagnosis of familial adenomatous polyposis (FAP).

The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients. Blood draws in FAP patients should always be accompanied by blood draws in their family member controls.

If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery.

Epi proColon Testing

Intervention Type OTHER

Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.

For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C.

Patient Group Lynch Syndrome

Clinical diagnosis of Lynch Syndrome, also known as HNPCC.

The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.

If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery.

Epi proColon Testing

Intervention Type OTHER

Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.

For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C.

Patient Group MAP / MYH

Clinical diagnosis of MYH-associated polyposis and presence of more than 20 colon polyps.

The patients of the disease and control groups participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. The follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating patients.

If colectomy is performed in a patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery.

Epi proColon Testing

Intervention Type OTHER

Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.

For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C.

Control Group (FAP Genetically-Related)

Genetically related family member of enrolled FAP patient.

Controls, i.e. relatives of patients: Willingness to give blood at each routine follow-up as advised for the diseased relative.

The patients of the control group participating in the study are followed up clinically and with blood draws at least every 6 months for the duration of 2 years. These follow-ups might be more frequent, if warranted by the clinical course of the individual disease in the participating FAP patients.

If colectomy is performed in a FAP patient of any disease group within the study participation period, additional blood draws will occur prior to any surgical bowel preparation and within a 28-day window after surgery.

Blood draws in FAP patients should always be accompanied by blood draws in their family member controls.

Epi proColon Testing

Intervention Type OTHER

Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.

For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Epi proColon Testing

Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.

For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent provided
* Age \> or = to 18 years of age
* Patient group FAP

\- Clinical diagnosis of familial adenomatous polyposis
* Patient group Lynch syndrome Clinical diagnosis of Lynch syndrome
* Patient group MAP

\- Clinical diagnosis of MYH-associated polyposis and presence of more than 20 colon polyps
* Control group (FAP)

\- Genetically related family member of patient
* Patients: Able and willing to attend routine follow-up as advised
* Controls, i.e. relatives of patients: Willingness to give blood at each routine follow-up as advised for the diseased relative

Exclusion Criteria

* Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV)
* Current diagnosis of colorectal cancer
* Pregnancy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes